Ethan V. Abel

Ethan V. Abel

Auto-generated profile, based on publicly available information

Ethan V. Abel

Department of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2018 in eLife
Verified
Journal Article
Open access
EAEthan V Abel
Ethan V Abel
MGMasashi Goto
Masashi Goto
BMBrian Magnuson
Brian Magnuson
SASaji Abraham
Saji Abraham
NRNikita Ramanathan
Nikita Ramanathan
DSDiane M Simeone
Diane M Simeone
The biological properties of pancreatic cancer stem cells (PCSCs) remain incompletely defined and the central regulators are unknown. By bioinformatic analysis of a human PCSC-enriched gene signature, we identified the transcription factor HNF1A as a putative central regulator of PCSC function. Levels of HNF1A and its target genes were found to be elevated in PCSCs and tumorspheres, and depletion of HNF1A resulted in growth inhibition, apoptosis, impaired tumorsphere formation, decreased PCSC marker expression, and downregulation of POU5F1/OCT4 expression. Conversely, HNF1A overexpression increased PCSC marker expression and tumorsphere formation in pancreatic cancer cells and drove pancreatic ductal adenocarcinoma (PDA) cell growth. Importantly, depletion of HNF1A in xenografts impaired tumor growth and depleted PCSC marker-positive cells in vivo. Finally, we established an HNF1A-dependent gene signature in PDA cells that significantly correlated with reduced survivability in patients. These findings identify HNF1A as a central transcriptional regulator of PCSC properties and novel oncogene in PDA.

31 January 2024 in Cancer Research
Verified
Journal Article
Open access
PDF file
VKVishnu Kumarasamy
Vishnu Kumarasamy
JWJianxin Wang
Jianxin Wang
CFCosta Frangou
Costa Frangou
YWYin Wan
Yin Wan
ADAndrew Dynka
Andrew Dynka
AWAgnieszka Witkiewicz
Agnieszka Witkiewicz
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease that lacks effective treatment options, highlighting the need for developing new therapeutic interventions. Here, we assessed the response to pharmacologic inhibition of KRAS, the central oncogenic driver of PDAC. In a panel of PDAC cell lines, inhibition of KRASG12D with MRTX1133 yielded variable efficacy in suppressing cell growth and downstream gene expression programs in 2D cultures. On the basis of CRISPR-Cas9 loss-of-function screens, ITGB1 was identified as a target to enhance the therapeutic response to MRTX1133 by regulating mechanotransduction signaling and YAP/TAZ expression, which was confirmed by gene-specific knockdown and combinatorial drug synergy. Interestingly, MRTX1133 was considerably more efficacious in 3D cell cultures. Moreover, MRTX1133 elicited a pronounced cytostatic effect in vivo and controlled tumor growth in PDAC patient-derived xenografts. In syngeneic models, KRASG12D inhibition led to tumor regression that did not occur in immune-deficient hosts. Digital spatial profiling on tumor tissues indicated that MRTX1133-mediated KRAS inhibition enhanced IFNγ signaling and induced antigen presentation that modulated the tumor microenvironment. Further investigation of the immunologic response using single-cell sequencing and multispectral imaging revealed that tumor regression was associated with suppression of neutrophils and influx of effector CD8+ T cells. Together, these findings demonstrate that both tumor cell-intrinsic and -extrinsic events contribute to response to MRTX1133 and credential KRASG12D inhibition as a promising therapeutic strategy for a large percentage of patients with PDAC. Significance: Pharmacologic inhibition of KRAS elicits varied responses in pancreatic cancer 2D cell lines, 3D organoid cultures, and xenografts, underscoring the importance of mechanotransduction and the tumor microenvironment in regulating therapeutic responses.

29 July 2025 in Molecular Cancer
Verified
Journal Article
Open access
KCKatherine J. Crawford
Katherine J. Crawford
KHKennedy S. Humphrey
Kennedy S. Humphrey
ECEduardo Cortes
Eduardo Cortes
JWJianxin Wang
Jianxin Wang
VKVishnu Kumarasamy
Vishnu Kumarasamy
EAEthan V. Abel
Ethan V. Abel
Background: We previously identified an oncogenic role for the transcription factor HNF1A in pancreatic ductal adenocarcinoma (PDAC). However, the role of HNF1A in the metastatic progression of PDAC remains unknown and targeting modalities for HNF1A-dependent phenotypes have yet to be identified. Methods: Transwell chambers were used to assess the effects of HNF1A and FGFR4 modulation on the migration and invasion of ATCC and patient-derived PDAC cells in vitro. An intrasplenic injection xenograft model was used to evaluate the impact of HNF1A knockdown and overexpression on metastatic tumor burden. Single-cell RNA sequencing (scRNA-seq), tissue microarray (TMA) data, and UMAP spatial profiling were used to identify FGFR4 as an HNF1A target gene upregulated in metastatic cells. RNAi and two FGFR4 inhibiting modalities (H3B-6527 and U3-1784) were utilized to demonstrate the efficacy of FGFR4 inhibiting agents at reducing HNF1A-driven metastasis. Results: Knockdown of HNF1A significantly decreases and HNF1A overexpression significantly increases PDAC cell migration and invasion. In vivo studies show that HNF1A knockdown significantly abrogates metastasis, while overexpression significantly promotes metastasis. scRNA-seq shows that FGFR4 is upregulated in metastatic PDAC cells and staining for HNF1A and FGFR4 in a PDAC TMA reveals significant correlation between HNF1A and FGFR4 in PDAC patients. Further, knockdown and inhibition of FGFR4 significantly decreases HNF1A-mediated cell migration and invasion, and blocks HNF1A-driven metastasis in vivo. Conclusions: These findings demonstrate that HNF1A drives PDAC metastasis via upregulation of FGFR4, and FGFR4 inhibition is a potential mechanism to target metastasis in PDAC patients.

12 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
VKVishnu Kumarasamy
Vishnu Kumarasamy
JWJianxin Wang
Jianxin Wang
EYEdwin Yau
Edwin Yau
EAEthan V. Abel
Ethan V. Abel
AWAgnieszka Witkiewicz
Agnieszka Witkiewicz
Erik KnudsenErik Knudsen
Erik Knudsen
Activating mutations in KRAS drive pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). Although mutant-selective KRAS inhibitors and pan-RAS inhibitors provide clinical benefits, the development of resistance limits durable response. Transcriptomic and proteomic analyses reveal that, despite effective suppression of mutant KRAS signaling, resistant cells sustain cell cycle progression. Distinct orthogonal mitogenic pathways are engaged in a context-dependent manner to bypass KRAS inhibition. While these pathways can be broadly inhibited using the pan-RAS-ON inhibitor RMC-6236, cells remained capable of developing acquired resistance where cell proliferation is uncoupled from RAS signaling. Combinatorial drug screens and genome-wide CRISPR-Cas9 screens reveal that perturbing cell cycle nodes via targeting cyclin dependent kinases CDK4/6 and CDK2 could restore sensitivity to KRAS/RAS inhibitors. Co-targeting CDK4/6 induces G1 arrest and suppresses E2F-regulated proteins across all resistant models. In contrast, co-targeting CDK2 exerts a broader effect by impairing DNA replication, inducing G2 arrest, preventing mitotic entry, and yielding a more durable cytostatic response that delays cellular outgrowth after drug withdrawal. Finally, concurrent inhibition of KRAS with either CDK4/6 or CDK2 yields durable tumor control in vivo in xenografts derived from acquired resistant models. In conclusion, our findings identify sustained cell cycle activity as a defining feature of resistance to KRAS-directed therapies and establish cell cycle co-targeting as an effective strategy to overcome KRAS/RAS inhibitor resistance.

2 October 2025 in bioRxiv
Verified
Preprint
Open access
KHKennedy S. Humphrey
Kennedy S. Humphrey
KCKatherine J. Crawford
Katherine J. Crawford
BMBharani Muppavarapu
Bharani Muppavarapu
MMMelanie M. Mayberry
Melanie M. Mayberry
WMWilliam Morris
William Morris
EAEthan V. Abel
Ethan V. Abel
Pancreatic ductal adenocarcinoma (PDAC) is an exceedingly lethal cancer that lacks actionable molecular drivers, limiting precision treatment options. We previously identified the transcription factor, HNF1A, as a novel driver of tumorigenesis and pancreatic cancer stem cell (PCSC) properties in PDAC; however, HNF1A-targeting modalities do not currently exist. Here we show that HNF1A is a direct target of the epigenetic reader protein, BRD4, and its expression is exquisitely sensitive to BET-inhibitors (BETi), which inhibit PDAC cell proliferation and block PCSC-properties in a panel of HNF1A-expressing cell lines and patient-derived xenograft cells. Remarkably, we report that the antineoplastic activity of BETi/BRD4 knockdown can be overcome by restoration of HNF1A expression, but not by re-expression of canonical BETi target MYC. RNA-sequencing analyses revealed that a subset of BETi-responsive transcripts is dependent on HNF1A expression, including receptor tyrosine kinases (RTKs), regulators and ligands. Consistent with these data, we found that HNF1A restoration rescued EGFR/ERBB3-signaling and the protective effects of HNF1A restoration could be overcome with EGFR-inhibitors. Furthermore, we found that expressions of HNF1A, BRD4, and ERBB3 were strongly correlated across PDAC patient samples using multispectral immunofluorescence, supporting a connection between these players in PDAC biology, and high expression of ERBB3 associated with better survival, supporting the clinical importance of this network in patient outcomes. These findings demonstrate that BETi can be used to ablate HNF1A expression and that the inhibition of HNF1A is critical for BETi activity, while supporting HNF1A as novel therapeutic target in PDAC. Significance: This study demonstrates that the oncogenic transcription factor HNF1A is a direct target of BRD4, and that the ablation of HNF1A by BET-inhibitors is central to their antineoplastic activity in PDAC.

8 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
KCKatherine J. Crawford
Katherine J. Crawford
KHKennedy S. Humphrey
Kennedy S. Humphrey
ECEduardo Cortes
Eduardo Cortes
JWJianxin Wang
Jianxin Wang
MFMichael Feigin
Michael Feigin
EAEthan V. Abel
Ethan V. Abel
Purpose: We previously identified an oncogenic role for the transcription factor HNF1A in pancreatic ductal adenocarcinoma (PDAC). However, the role of HNF1A in the metastatic progression of PDAC remains unknown and targeting modalities for HNF1A -dependent phenotypes have yet to be identified. Experimental Design: Transwell chambers were used to assess the effects of HNF1A and FGFR4 modulation on the migration and invasion of ATCC and patient-derived PDAC cells in vitro . An intrasplenic injection xenograft model was used to evaluate the impact of HNF1A knockdown and overexpression on metastatic tumor burden. Single-cell RNA sequencing, tissue microarray (TMA) data, and UMAP spatial profiling were used to identify FGFR4 as an HNF1A target gene upregulated in metastatic cells. RNAi and two FGFR4 inhibiting modalities (H3B-6527 and U3- 1784) were utilized to demonstrate the efficacy of FGFR4 inhibiting agents at reducing HNF1A- driven metastasis. Results: Knockdown of HNF1A significantly decreases and HNF1A overexpression significantly increases PDAC cell migration and invasion. In vivo studies show that HNF1A knockdown significantly abrogates metastasis, while overexpression significantly promotes metastasis. Single-cell RNAseq shows that FGFR4 is upregulated in metastatic PDAC cells and staining for HNF1A and FGFR4 in a PDAC TMA reveals significant correlation between HNF1A and FGFR4 in PDAC patients. Further, knockdown and inhibition of FGFR4 significantly decreases HNF1A- mediated cell migration and invasion, and blocks HNF1A-driven metastasis in vivo . Conclusions: These findings demonstrate that HNF1A drives PDAC metastasis via upregulation of FGFR4, and FGFR4 inhibition is a potential mechanism to target metastasis in PDAC patients. Translational Relevance: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, made even more devastating when metastases overwhelm major organs. The vast majority of PDAC patients either present with metastases or will relapse with recurrent metastatic PDAC after primary tumor resection. Unfortunately, toxic and largely ineffective chemotherapies are currently the only approved treatment options for these patients and therefore there exists a critical and unmet clinical need for targeted therapies against pro-metastatic pathways in PDAC. In the current study, we identify HNF1A as an oncogenic transcription factor that drives metastasis in PDAC, and it does so through upregulation of the receptor tyrosine kinase FGFR4. Importantly, FGFR4 is a targetable vulnerability and treatment with an FGFR4 blocking antibody reduces HNF1A-driven metastasis. These findings suggest that FGFR4 inhibitors could be an efficacious treatment for PDAC patients for the prevention or delay of metastatic tumor development.